Michael John Swartz MD

Radiation Oncology•Rapid City, SD

Physician

Join to View Full Profile

353 Fairmont BlvdRapid City, SD 57701
Phone+1 605-719-8559
Fax+1 605-719-2310

Education & Training

Johns Hopkins UniversityResidency, Radiation Oncology, 2004 - 2008
MedStar Franklin Square Medical CenterInternship, Internal Medicine, 2003 - 2004
Johns Hopkins University School of MedicineClass of 2003

Certifications & Licensure

SD State Medical License Active through 2027
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013

Clinical Trials

Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Start of enrollment: 2005 Mar 01
Completed
Not Applicable
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
ACTIVE_NOT_RECRUITING
PHASE3
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Start of enrollment: 2008 Jun 01
Completed
Phase 3
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2009 Apr 15
Completed
Phase 3
Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis Start of enrollment: 2009 Nov 01
Completed
Phase 2, Phase 3
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
ACTIVE_NOT_RECRUITING
PHASE3
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Start of enrollment: 2010 Mar 31
Active, not recruiting
Phase 3
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
ACTIVE_NOT_RECRUITING
PHASE3
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Start of enrollment: 2010 Apr 05
ACTIVE_NOT_RECRUITING
PHASE3
Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2010 Mar 01
Completed
Phase 2
Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery Start of enrollment: 2010 Jun 01
Completed
Phase 2
Radiation Therapy with or Without Chemotherapy in Treating Patients with High-Risk Malignant Salivary Gland Tumors That Have Been Removed by Surgery
ACTIVE_NOT_RECRUITING
PHASE2
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Start of enrollment: 2011 Mar 01
Completed
Phase 2
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
ACTIVE_NOT_RECRUITING
PHASE3
Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Start of enrollment: 2011 May 24
ACTIVE_NOT_RECRUITING
PHASE3
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
ACTIVE_NOT_RECRUITING
PHASE3
Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Start of enrollment: 2012 Nov 01
Completed
Phase 3
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer Start of enrollment: 2013 Mar 22
RECRUITING
PHASE2, PHASE3
Join now to see all

Publications & Presentations

PubMed

41 citations
Early Mortality Risk Score: Identification of Poor Outcomes Following Upfront Surgery for Resectable Pancreatic Cancer
Charles C. Hsu, Christopher L. Wolfgang, Daniel A. Laheru, Timothy M. Pawlik, Michael J. Swartz
Journal of Gastrointestinal Surgery. 2012-02-07
49 citations
Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas.
Michael J. Swartz, Charles C. Hsu, Timothy M. Pawlik, Jordan M. Winter, Ralph H. Hruban
International Journal of Radiation Oncology, Biology, Physics. 2010-03-01
178 citations
Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study
Charles C. Hsu, Joseph M. Herman, Michele M. Corsini, Jordan M. Winter, Matthew D. Callister
Annals of Surgical Oncology. 2010-01-20

Press Mentions

BioSpace Movers & Shakers, Aug. 27August 27th, 2021
AstraZeneca Promotes Oncology Exec to CMO; Pfizer Replaces Retiring Chief Dealmaker as War Chest ExpandsAugust 27th, 2021
MediXall Group Hires Leading PR Firm, TransMedia Group, to Drive Brand Awareness & Media Relations to Propel Health Karma on Its Next Phase of GrowthAugust 5th, 2021
Join now to see all

Michael John Swartz MD

Dr. Swartz is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.